Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerucin for P. aeruginosa Pneumonia
NCT03027609Phase 2Completed
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 17
01
Overview
A Phase 2 trial of aerucin in Pseudomonas aeruginosa pneumonia, sponsored by Aridis Pharmaceuticals, Inc.. Started Mar 2017; status: completed.
02
Drugs
aerucin
03
Conditions
Pseudomonas aeruginosa pneumonia
Beyond the preview
Go deeper on NCT03027609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027609.